

Impact of Living with Low-Grade Serous Ovarian Cancer (LGSOC)

Results from the multinational LGSOC Patient Impact Survey

Low Awareness and Knowledge

Among those diagnosed with LGSOC, there is virtually no awareness about this cancer prior to diagnosis, and 60% did not feel that their healthcare provider (HCP) was “very knowledgeable” about this rare cancer.¹

99%

Of people with LGSOC had never heard of the condition before they were diagnosed¹

65%

Agree that if they had known more about LGSOC, they probably would have been diagnosed sooner¹

ONLY

1 in 4

Are satisfied with the amount of LGSOC information available (26%)¹

Misdiagnosed and Dismissed



Average amount of time that passed before diagnosis (among the 81% who experienced symptoms)¹

MORE THAN

2 in 3

Found their path to LGSOC diagnosis **difficult** (73%) or **frustrating** (68%)¹

59%

Are **not satisfied** with how long it took to be diagnosed¹

68%

Of those who experienced symptoms report that their HCP attributed their symptoms to another health condition¹

66%

Agree that, before they were diagnosed with LGSOC, they felt their symptoms were dismissed by their HCP¹

Challenges with Treatment and Emotional Impact

Biggest challenges people with LGSOC face in managing their condition

68%

Living with uncertainty¹

60%

Limited treatment options¹

52%

Treatment side effects¹

48%

Anxiety or worry¹

When they finally received an LGSOC diagnosis, patients report that their treatment options are limited:

90%

Feel like they are getting the “treatment leftovers” instead of treatment regimens that have been studied specifically in LGSOC¹

41%

Feeling like their lives revolve around cancer¹

25%

Reported having to pause or stop treatment altogether because of side effects¹

Call for Resources and Attention

ONLY

42%

Are satisfied with available resources dedicated to patients with LGSOC¹

88%

Strongly agree that they wish more attention was paid to LGSOC as its own distinct disease¹

TOP ITEM PEOPLE LIVING WITH LGSOC WANT WOMEN TO KNOW ABOUT

Symptoms can be easily misdiagnosed as something else (87%)¹

Learn More

To view survey details, including methodology, audience demographics, survey data and more, [click here](#).

About the survey: The LGSOC Patient Impact Survey was conducted online by The Harris Poll on behalf of the LGSOC Patient Impact Advisory Committee – a global collaboration among patient advocacy groups, including STAAR Ovarian Cancer Foundation (STAAR), Cure Our Ovarian Cancer and the World Ovarian Cancer Coalition (WOCC), leaders in the medical community and supported by Verastem Oncology – among 186 women ages 18+ who have been diagnosed with low-grade serous ovarian cancer across 10+ countries. The survey was conducted July 31st - August 29th 2023. Raw data were not weighted and are therefore only representative of the individuals who completed the survey.

References

¹ LGSOC Patient Impact Survey Research Findings. Harris Poll. 2023. ² Grisham, R. Low Grade Serous Carcinoma of the Ovary. *Oncology*. 2016. 30(7):650-652. <https://www.cancer-network.com/view/low-grade-serous-carcinoma-of-the-ovary>. ³ Slomovitz B, Gourley C, Carey S, M, Malpica A, Shih I, Huntsman D, et al. Low-Grade serous ovarian cancer: State of the Science. *Gynecol Oncol*. 2020;156(3):715-725. <https://doi.org/10.1016/j.ygyno.2019.12.033>.

About LGSOC: Low-grade serous ovarian cancer (LGSOC) is a rare, highly recurrent ovarian cancer, associated with slow but persistent tumor growth and a high mortality rate.² It commonly affects younger women than its high-grade counterpart with a median age at diagnosis between 45-55.³ For many, the disease and its treatment will cause a significant amount of pain and impact on their lives over a long period of time and a long-lasting impact on mental and physical health, including fertility and early menopause.³